Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Global $1.9 Bn 3D Bioprinters Market to 2025


DUBLIN, October 18, 2017 /PRNewswire/ --

The "Global 3D Bioprinters Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025" report has been added to Research and Markets' offering.

Research and Markets Logo

The 3D bioprinters market was valued at USD 774.41 Mn in 2017, and is expected to reach USD 1,942.5 Mn by 2025, expanding at a CAGR of 18.8% from 2017 - 2025.

The global 3D bioprinters market is represented by key technologies namely, syringe based 3D bioprinting, laser based 3D bioprinting, magnetic levitation 3D bioprinting, inkjet based 3D bioprinting and valve-based 3D bioprinting. Among these syringe based 3D bioprinting is the largest segment and is anticipated to maintain its lead during the forecast period 2016 - 2022.

Pharmaceuticals segment accounted for a major share of 31.70% in the 3D bioprinting market. Drug development today is increasingly focusing on reducing side effects, improving treatment outcomes and deserting the one-size-fits-all' approach to medication management.

According to market experts competition in 3D bioprinting market is low and barriers are high. Competition is low due to presence of niche opportunities in the healthcare industry and barriers are high because the research is very specialized and requires a significant amount of investment, usually by the government or private donors, while the risks to profitability remain very high.

3D Systems, Inc. and Stratasys Ltd. dominate the 3D printer applications in healthcare market. The other upcoming key players such as Organovo, Inc. and EnvisionTEC, Inc. are expected to be one of the leading players in 3D bioprinting market in the near future.

Market Dynamics

Drivers

Challenges

Opportunities

Key Market Movements:

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 3D Bioprinters Market: Market Dynamics and Outlook

Chapter 4 Global 3D Bioprinters Market, by Technology

Chapter 5 Global 3D Bioprinters Market, by Application

Chapter 6 Global 3D Bioprinters Market, By Geography

Chapter 7 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/qr3sf9/global_3d

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


These press releases may also interest you

at 01:17
Quarter 1, 2024 - High profitability and strong cash flow Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...



News published on and distributed by: